{"organizations": [], "uuid": "e4439a35994e0937e390af76917c92872c980ebf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-achillion-reports-q1-loss-per-shar/brief-achillion-reports-q1-loss-per-share-0-15-idUSASC09YWR", "country": "US", "domain_rank": 408, "title": "BRIEF-Achillion Reports Q1 Loss Per Share $0.15", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T13:40:00.000+03:00", "replies_count": 0, "uuid": "e4439a35994e0937e390af76917c92872c980ebf"}, "author": "", "url": "https://www.reuters.com/article/brief-achillion-reports-q1-loss-per-shar/brief-achillion-reports-q1-loss-per-share-0-15-idUSASC09YWR", "ord_in_thread": 0, "title": "BRIEF-Achillion Reports Q1 Loss Per Share $0.15", "locations": [], "entities": {"persons": [{"name": "milind deshpande", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "achillion pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 10:43 AM / Updated 2 minutes ago BRIEF-Achillion Reports Q1 Loss Per Share $0.15 Reuters Staff\nMay 2 (Reuters) - Achillion Pharmaceuticals Inc:\n* ACHILLION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND MANAGEMENT TRANSITION * Q1 LOSS PER SHARE $0.15\n* Q1 EARNINGS PER SHARE VIEW $-0.14 â€” THOMSON REUTERS I/B/E/S * MILIND DESHPANDE WILL BE STEPPING DOWN\n* PLANS FOR CLINICAL DATA IN C3 GLOMERULOPATHY AND FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REMAIN ON TRACK FOR 2018\n* ACHILLION - $1.8 MILLION CHARGES IN QUARTER CONSIST OF EMPLOYEE SEVERANCE PAYMENTS RESTRUCTURING PLAN WHICH REDUCED EMPLOYEE HEADCOUNT BY ABOUT 20% Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T13:40:00.000+03:00", "crawled": "2018-05-02T13:53:36.008+03:00", "highlightTitle": ""}